Comparative Effects of Intravenous Versus Intranasal Dexmedetomidine on Cardiac Function in Patients with Sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511730546627

Enrollment

Registered

2025-11-13

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Intravenous Dexmedetomidine

Intranasal Dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Age: 18 - 65 years. • Sex: both males and females. • Diagnosis of sepsis or septic shock according to Sepsis-3 criteria [1]. • ICU admission within the last 12 hours. • Indicated for sedation (e.g. need for mechanical ventilation).

Exclusion criteria

Exclusion criteria: • Pre-existing severe heart failure (EF < 40%). • Recent myocardial infarction (within 30 days). • Bradycardia (HR < 50 bpm) or heart block. • Severe neurologic impairment or brain death. • Allergy or contraindication to dexmedetomidine. • Do-Not-Resuscitate (DNR) status.

Design outcomes

Primary

Measure	Time frame
left ventricular ejection fraction will be measured by transthoracic echocardiography (TTE)	—

Secondary

Measure	Time frame
Levels of cardiac injury biomarker (Troponin I)	—

Countries

Egypt

Contacts

Public ContactMostafa Ali

Resident of Anaesthesia ICU and Pain management

Moustafa.17289915@med.aun.edu.eg+201116606632

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026